https://www.selleckchem.com/pr....oducts/cloperastine-
Medicaid recipients have a high burden of opioid overdose and opioid use disorder (OUD). Opioid agonist therapies are an effective treatment for OUD, but there is a wide and persisting gap between those who are indicated and those who receive treatment. The objective of this study was to identify the predictors of enrollment in opioid agonist therapy within 6 months of an opioid overdose or OUD diagnosis in a cohort of Medicaid recipients. Using multiple linked, state-level databases, we conducted a retrospective cohort
Like
Comment
Share
